Microbiome in cystic fibrosis: Shaping polymicrobial interactions for advances in antibiotic therapy

Critical Reviews in Microbiology

Volumn 41, Issue 3, 2015, Pages 353-365

  Lopes, Susana P ^a   Azevedo, Nuno F ^b   Pereira, Maria O ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Antibiotic therapy; Cystic fibrosis; Microbial diversity; Microbial interactions; Polymicrobial biofilms

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CFTR PROTEIN, HUMAN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; CHRONIC DISEASE; CYSTIC FIBROSIS; HOST PATHOGEN INTERACTION; HUMAN; MICROBIAL COMMUNITY; MICROBIOME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; GENETICS; MICROBIOLOGY; MICROFLORA; RESPIRATORY SYSTEM;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MICROBIOTA; RESPIRATORY SYSTEM;

EID: 84953864937     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.3109/1040841X.2013.847898     Document Type: Review

References (124)

1. Andersen DH. (1938), Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathological study. Am J Dis Child 56: 344-99.
2. Bakare N, Rickerts V, Bargon J, Just-Nubling G. (2003), Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 46: 19-23.
3. Balfour-Lynn IA, Elborn JS. (2007), Respiratory disease: Infection. In: Hodson M, Bush A, and Geddes DM, ed. Cystic fibrosis. London: Hodder Arnold, 137-58.
4. Barton RC, Borman AM, Johnson EM, et al. (2010), Isolation of the fungus Geosmithia argillacea in sputum of people with cystic fibrosis. J Clin Microbiol 48: 2615-7.
5. Bittar F, Cassagne C, Bosdure E, et al. (2010), Outbreak of Corynebacterium pseudodiphtheriticum infection in cystic fibrosis patients, France. Emerg Infect Dis 16: 1231-6.
6. Bittar F, Richet H, Dubus JC, et al. (2008), Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 3: E2908.
7. Bittar F, Rolain JM. (2010), Detection and accurate identification of new or emerging bacteria in cystic fibrosis patients. Clin Microbiol Infect 16: 809-20.
8. Blyth CC, Harun A, Middleton PG, et al. (2010), Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. J Clin Microbiol 48: 314-6.
9. Borriello G, Werner E, Roe F, et al. (2004), Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother 48: 2659-64.
10. Boucher RC. (2004), Relationship of airway epithelial ion transport to chronic bronchitis. Proc Am Thorac Soc 1: 66-70.
11. Bouchara JP, Hsieh HY, Croquefer S, et al. (2009), Development of an oligonucleotide array for direct detection of fungi in sputum samples from patients with cystic fibrosis. J Clin Microbiol 47: 142-52.
12. Burns JL, Emerson J, Stapp JR, et al. (1998), Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 27: 158-63.
13. Carmody LA, Gill JJ, Summer EJ, et al. (2010), Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201: 264-71.
14. Carmody LA, Zhao J, Schloss PD, et al. (2013), Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc 10: 179-87.
15. Chmiel JF, Konstan MW, Elborn JS. (2013), Antibiotic and Anti-Inflammatory Therapies for Cystic Fibrosis. Cold Spring Harb Perspect Med 3: A009779.
16. Chotirmall SH, O'Donoghue E, Bennett K, et al. (2010), Sputum Candida albicans Presages Fev1 decline and hospitalized exacerbations in cystic fibrosis. Chest 138: 1186-95.
17. Cimon B, Carrere J, Chazalette JP, et al. (1999), Chronic airway colonization by Penicillium emersonii in a patient with cystic fibrosis. Med Mycol 37: 291-3.
18. Cimon B, Carrère J, Chazalette JP, et al. (2000), Bronchopulmonary mycoses in cystic fibrosis. Results of a longitudinal epidemiologic study over a five-year period. J Med Mycol 10: 128-35.
19. Cimon B, Challier S, Beguin H, et al. (2005), Airway colonization by Acrophialophora fusispora in patients with cystic fibrosis. J Clin Microbiol 43: 1484-7.
20. Coenye T, Goris J, Spilker T, et al. (2002), Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. Nov. J Clin Microbiol 40: 2062-9.
21. Conrad D, Haynes M, Salamon P, et al. (2013), Cystic fibrosis therapy: A community ecology perspective. Am J Respir Cell Mol Biol 48: 150-6.
22. Costello A, Herbert G, Fabunmi L, et al. (2011), Virulence of an emerging respiratory pathogen, genus Pandoraea, in vivo and its interactions with lung epithelial cells. J Med Microbiol 60: 289-99.
23. Cox MJ, Allgaier M, Taylor B, et al. (2010), Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5: E11044.
24. de Almeida MB, Bussamra MH, Rodrigues JC. (2006), Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev 7: 67-72.
25. de Almeida MB, Zerbinati RM, Tateno AF, et al. (2010), Rhinovirus C and respiratory exacerbations in children with cystic fibrosis. Emerg Infect Dis 16: 996-9.
26. Defontaine A, Zouhair R, Cimon B, et al. (2002), Genotyping study of Scedosporium apiospermum isolates from patients with cystic fibrosis. J Clin Microbiol 40: 2108-14.
27. Delhaes L, Monchy S, Frealle E, et al. (2012), The airway microbiota in cystic fibrosis: A complex fungal and bacterial community -implications for therapeutic management. PLoS One 7: E36313.
28. Diemert D, Kunimoto D, Sand C, Rennie R. (2001), Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scand J Infect Dis 33: 777-9.
29. Donlan RM. (2009), Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol 17: 66-72.
30. Doring G, Flume P, Heijerman H, et al. (2012), Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. J Cyst Fibros 11: 461-79.
31. Duan K, Dammel C, Stein J, et al. (2003), Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol Microbiol 50: 1477-91.
32. Fancello L, Desnues C, Raoult D, Rolain JM. (2011), Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemother 66: 2448-54.
33. Frey-Klett P, Burlinson P, Deveau A, et al. (2011), Bacterial-fungal interactions: Hyphens between agricultural, clinical, environmental, and food microbiologists. Microbiol Mol Biol Rev 75: 583-609.
34. Gal SL, Hery-Arnaud G, Ramel S, et al. (2010), Pneumocystis jirovecii and cystic fibrosis in France. Scand J Infect Dis 42: 225-7.
35. Gilgado F, Serena C, Cano J, et al. (2006), Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 50: 4211-3.
36. Giraud S, Pihet M, Razafimandimby B, et al. (2010), Geosmithia argillacea: An emerging pathogen in patients with cystic fibrosis. J Clin Microbiol 48: 2381-6.
37. Glonti T, Chanishvili N, Taylor PW. (2010), Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa. J Appl Microbiol 108: 695-702.
38. Griffard EA, Guajardo JR, Cooperstock MS, Scoville CL. (2010), Isolation of Exophiala dermatitidis from pigmented sputum in a cystic fibrosis patient. Pediatr Pulmonol 45: 508-10.
39. Guss AM, Roeselers G, Newton IL, et al. (2011), Phylogenetic and metabolic diversity of bacteria associated with cystic fibrosis. ISME J 5: 20-9.
40. Hansen SK, Rainey PB, Haagensen JAJ, Molin S. (2007), Evolution of species interactions in a biofilm community. Nature 445: 533-6.
41. Harris JK, De Groote MA, Sagel SD, et al. (2007), Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci USA 104: 20529-33.
42. Hassett DJ, Cuppoletti J, Trapnell B, et al. (2002), Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: Rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 54: 1425-43.
43. Hauser AR, Jain M, Bar-Meir M, McColley SA. (2011), Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 24: 29-70.
44. Heijerman H. (2005), Infection and inflammation in cystic fibrosis: A short review. J Cyst Fibros 4: 3-5.
45. Hélène M, Anne-Laure M, Estelle J-B. (2012), Atypical bacteria in the CF airways: Diversity, clinical consequences, emergence and adaptation. In: Sriramulu DD, ed. Cystic fibrosis -renewed hopes through research. Rijeka, Croatia: InTech, 225-52.
46. Hickey PW, Sutton DA, Fothergill AW, et al. (2009), Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosis. J Clin Microbiol 47: 3091-7.
47. Hoffman LR, Deziel E, D'Argenio DA, et al. (2006), Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 103: 19890-5.
48. Hoiby N. (2011), Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med 9: 32.
49. Hoiby N, Bjarnsholt T, Givskov M, et al. (2010b), Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322-32.
50. Hoiby N, Ciofu O, Bjarnsholt T. (2010a), Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5: 1663-74.
51. Hoiby N, Krogh Johansen H, et al. (2001), Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 3: 23-35.
52. Holcombe LJ, McAlester G, Munro CA, et al. (2010), Pseudomonas aeruginosa secreted factors impair biofilm development in Candida albicans. Microbiology 156: 1476-86.
53. Horre R, Schaal KP, Siekmeier R, et al. (2004), Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis. A prospective study. Respiration 71: 360-6.
54. Hsieh SE, Lo HH, Chen ST, et al. (2011), Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol 77: 756-61.
55. Kalka-Moll WM, LiPuma JJ, Accurso FJ, et al. (2009), Airway infection with a novel Cupriavidus species in persons with cystic fibrosis. J Clin Microbiol 47: 3026-8.
56. Kenna DT, Doherty CJ, Foweraker J, et al. (2007), Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 153: 1852-9.
57. Khanbabaee G, Akbarizadeh M, Sayyari A, et al. (2012), A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. Braz J Infect Dis 16: 122-8.
58. Kieninger E, Singer F, Tapparel C, et al. (2013), High rhinovirus burden in lower airways of children with cystic fibrosis. Chest 143: 782-90.
59. Klepac-Ceraj V, Lemon KP, Martin TR, et al. (2010), Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol 12: 1293-303.
60. Kusenbach G, Skopnik H, Haase G, et al. (1992), Exophiala dermatitidis pneumonia in cystic fibrosis. Eur J Pediatr 151: 344-6.
61. Lambiase A, Raia V, Del Pezzo M, et al. (2006), Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis 6: 4.
62. Leao RS, Pereira RH, Ferreira AG, et al. (2010), First report of Paenibacillus cineris from a patient with cystic fibrosis. Diagn Microbiol Infect Dis 66: 101-3.
63. Lipuma JJ. (2010), The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 23: 299-323.
64. Lopes SP, Ceri H, Azevedo NF, Pereira MO. (2012), Antibiotic resistance of mixed biofilms in cystic fibrosis: Impact of emerging microorganisms on treatment of infection. Int J Antimicrob Agents 40: 260-3.
65. Loutet SA, Valvano MA. (2010), A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun 78: 4088-100.
66. Lumb R, Greville H, Martin J, et al. (2002), Nocardia asteroides isolated from three patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 21: 230-3.
67. Lubamba B, Dhooghe B, Noel S, Leal T. (2012), Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy. Clin Biochem 45: 1132-44.
68. Lyczak JB, Cannon CL, Pier GB. (2002), Lung infections associated with cystic fibrosis. Clin Microbiol Rev 15: 194-222.
69. Lynch SV, Bruce KD. (2013), The cystic fibrosis airway microbiome. Cold Spring Harb Perspect Med 3: A009738.
70. Menuet M, Bittar F, Stremler N, et al. (2008), First isolation of two colistin-resistant emerging pathogens, Brevundimonas diminuta and Ochrobactrum anthropi, in a woman with cystic fibrosis: A case report. J Med Case Rep 2: 373-6.
71. Miller MB, Gilligan PH. (2003), Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 41: 4009-15.
72. Morello E, Saussereau E, Maura D, et al. (2011), Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: First steps towards treatment and prevention. PLoS One 6: E16963.
73. Mowat E, Rajendran R, Williams C, et al. (2010), Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 313: 96-102.
74. Nagano Y, Millar BC, Goldsmith CE, et al. (2007), Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch Dis Child 92: 607.
75. Olesen HV, Nielsen LP, Schiotz PO. (2006), Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic. Pediatr Pulmonol 41: 1197-204.
76. Palmer KL, Aye LM, Whiteley M. (2007), Nutritional cues control Pseudomonas aeruginosa multicellular behavior in cystic fibrosis sputum. J Bacteriol 189: 8079-87.
77. Pederiva MA, Wissmann G, Friaza V, et al. (2012), High prevalence of Pneumocystis jirovecii colonization in Brazilian cystic fibrosis patients. Med Mycol 50: 556-60.
78. Peters BM, Jabra-Rizk MA, O'May GA, et al. (2012), Polymicrobial interactions: Impact on pathogenesis and human disease. Clin Microbiol Rev 25: 193-213.
79. Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, et al. (2005), Agerelated prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 43: 3467-70.
80. Pompilio A, Crocetta V, Confalone P, et al. (2010), Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiol 10: 102.
81. Punch G, Syrmis MW, Rose BR, et al. (2005), Method for detection of respiratory viruses in the sputa of patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 24: 54-7.
82. Radlovic N. (2012), Cystic fibrosis. Srp Arh Celok Lek 140: 244-9.
83. Rajan S, Saiman L. (2002), Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 17: 47-56.
84. Rogers GB, Carroll MP, Serisier DJ, et al. (2004), Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 42: 5176-83.
85. Rogers GB, Hart CA, Mason JR, et al. (2003), Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol 41: 3548-58.
86. Rogers GB, Hoffman LR, Whiteley M, et al. (2010b), Revealing the dynamics of polymicrobial infections: Implications for antibiotic therapy. Trends Microbiol 18: 357-64.
87. Rogers GB, Stressmann FA, Walker AW, et al. (2010a), Lung infections in cystic fibrosis: Deriving clinical insight from microbial complexity. Expert Rev Mol Diagn 10: 187-96.
88. Rolain JM, Fancello L, Desnues C, Raoult D. (2011), Bacteriophages as vehicles of the resistome in cystic fibrosis. J Antimicrob Chemother 66: 2444-7.
89. Rolain JM, Francois P, Hernandez D, et al. (2009), Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol Direct 4: 1-15.
90. Sagel SD, Gibson RL, Emerson J, et al. (2009), Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 154: 183-8.
91. Saiman L, Siegel J. (2004), Infection control in cystic fibrosis. Clin Microbiol Rev. 17: 57-71.
92. Schelstraete P, Haerynck F, Van Daele S, et al. (2013), Eradication therapy for Pseudomonas aeruginosa colonization episodes in cystic fibrosis patients not chronically colonized by P. aeruginosa. J Cyst Fibros 12: 1-8.
93. Sibley CD, Parkins MD, Rabin HR, Surette MG. (2009), The relevance of the polymicrobial nature of airway infection in the acute and chronic management of patients with cystic fibrosis. Curr Opin Investig Drugs 10: 787-94.
94. Sibley CD, Parkins MD, Rabin HR, et al. (2008), A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci USA 105: 15070-5.
95. Sibley CD, Rabin H, Surette MG. (2006), Cystic fibrosis: A polymicrobial infectious disease. Future Microbiol 1: 53-61.
96. Smith AL, Fiel SB, Mayer-Hamblett N, et al. (2003), Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: Lack of association in cystic fibrosis. Chest 123: 1495-502.
97. Smith CB, Golden C, Klauber MR, et al. (1976), Interactions between viruses and bacteria in patients with chronic bronchitis. J Infect Dis 134: 552-61.
98. Smyth AR, Smyth RL, Tong CY, et al. (1995), Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child 73: 117-20.
99. Spicuzza L, Sciuto C, Vitaliti G, et al. (2009), Emerging pathogens in cystic fibrosis: Ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis 28: 191-5.
100. Starner TD, Zhang N, Kim G, et al. (2006), Haemophilus influenzae forms biofilms on airway epithelia: Implications in cystic fibrosis. Am J Respir Crit Care Med 174: 213-20.
101. Steinkamp G, Tummler B, Malottke R, von der Hardt H. (1989), Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Arch Dis Child 64: 1022-8.
102. Suppiger A, Schmid N, Aguilar C, et al. (2013), Two quorum sensing systems control biofilm formation and virulence in members of the Burkholderia cepacia complex. Virulence 4: 400-9.
103. Tomee JF, Wierenga AT, Hiemstra PS, Kauffman HK. (1997), Proteases from Aspergillus fumigatus induce release of proinflammatory cytokines and cell detachment in airway epithelial cell lines. J Infect Dis 176: 300-3.
104. Tomlin KL, Coll OP, Ceri H. (2001), Interspecies biofilms of Pseudomonas aeruginosa and Burkholderia cepacia. Can J Microbiol 47: 949-54.
105. Torrens JK, Dawkins P, Conway SP, Moya E. (1998), Non-Tuberculous mycobacteria in cystic fibrosis. Thorax 53: 182-5.
106. Touw DJ, Brimicombe RW, Hodson ME, et al. (1995), Inhalation of antibiotics in cystic fibrosis. Eur Respir J 8: 1594-604.
107. Tunney MM, Field TR, Moriarty TF, et al. (2008), Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 177: 995-1001.
108. Twomey KB, O'Connell OJ, McCarthy Y, et al. (2012), Bacterial cis-2-unsaturated fatty acids found in the cystic fibrosis airway modulate virulence and persistence of Pseudomonas aeruginosa. ISME J 6: 939-50.
109. Ulrich M, Beer I, Braitmaier P, et al. (2010), Relative contribution of Prevotella intermedia and Pseudomonas aeruginosa to lung pathology in airways of patients with cystic fibrosis. Thorax 65: 978-84.
110. Valenza G, Tappe D, Turnwald D, et al. (2008), Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 7: 123-7.
111. Vandamme P, Holmes B, Coenye T, et al. (2003), Burkholderia cenocepacia sp. Nov. -A new twist to an old story. Res Microbiol 154: 91-6.
112. Wark PA, Tooze M, Cheese L, et al. (2012), Viral infections trigger exacerbations of cystic fibrosis in adults and children. Eur Respir J 40: 510-2.
113. Warren TA, Yau Y, Ratjen F, et al. (2012), Serum galactomannan in cystic fibrosis patients colonized with Aspergillus species. Med Mycol 50: 658-60.
114. Wat D, Gelder C, Hibbitts S, et al. (2008), The role of respiratory viruses in cystic fibrosis. J Cyst Fibros 7: 320-8.
115. Waters VJ, Gomez MI, Soong G, et al. (2007), Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 75: 1698-703.
116. Watson Jr. ME, Burns JL, Smith AL. (2004), Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150: 2947-58.
117. Willner D, Furlan M, Haynes M, et al. (2009), Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and noncystic fibrosis individuals. PLoS One 4: E7370.
118. Willner D, Haynes MR, Furlan M, et al. (2012), Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lung. Am J Respir Cell Mol Biol 46: 127-31.
119. Worlitzsch D, Rintelen C, Bohm K, et al. (2009), Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 15: 454-60.
120. Worlitzsch D, Tarran R, Ulrich M, et al. (2002), Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317-25.
121. Yang L, Haagensen JA, Jelsbak L, et al. (2008), In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infections. J Bacteriol 190: 2767-76.
122. Yang L, Jelsbak L, Molin S. (2011), Microbial ecology and adaptation in cystic fibrosis airways. Environ Microbiol 13: 1682-9.
123. Yoon SS, Hennigan RF, Hilliard GM, et al. (2002), Pseudomonas aeruginosa anaerobic respiration in biofilms: Relationships to cystic fibrosis pathogenesis. Dev Cell 3: 593-603.
124. Zhao JC, Schloss PD, Kalikin LM, et al. (2012), Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci USA 109: 5809-14.